- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
Patent holdings for IPC class A61K 31/553
Total number of patents in this class: 2332
10-year publication summary
|
122
|
110
|
135
|
110
|
131
|
125
|
140
|
233
|
245
|
10
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Genentech, Inc. | 4014 |
84 |
| Gilead Sciences, Inc. | 2113 |
80 |
| Amgen Inc. | 4275 |
49 |
| AstraZeneca AB | 2835 |
41 |
| F. Hoffmann-La Roche AG | 7896 |
39 |
| Rigel Pharmaceuticals, Inc. | 528 |
38 |
| Takeda Pharmaceutical Company Limited | 2707 |
37 |
| Boehringer Ingelheim International GmbH | 4591 |
35 |
| Merck Sharp & Dohme LLC | 3737 |
32 |
| Novartis AG | 10506 |
31 |
| Bristol-myers Squibb Company | 4793 |
29 |
| Eli Lilly and Company | 3949 |
23 |
| Insmed Incorporated | 250 |
23 |
| VALO Health, Inc. | 181 |
22 |
| Janssen Pharmaceutica N.V. | 3345 |
21 |
| Glaxosmithkline Intellectual Property Development Limited | 775 |
21 |
| Daiichi Sankyo Company, Limited | 1877 |
21 |
| The Trustees of Columbia University in the City of New York | 3599 |
20 |
| Vertex Pharmaceuticals Incorporated | 1629 |
18 |
| Taisho Pharmaceutical Co., Ltd. | 867 |
17 |
| Other owners | 1651 |